Andere Sprachen Mabpharm Limited

Aktien

A2PK2Q

KYG5780F1046

2181

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:20 26.04.2024			% 5 Tage	% 1. Jan.
0,415 ^HKD	0,00 %		-2,35 %	-9,78 %

26.03.	Mabpharm Limited meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
10.01.	Livzon Pharma verbucht Wertminderungen bei Krediten und Vermögenswerten	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Livzon Pharma Recognizes Credit, Asset Impairments	10.01.
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use	04.12.
Mabpharm Limited Announces Director Changes	28.11.
Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	13.11.
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2023	25.08.23
China Grants Nod to Livzon Pharmaceutical Subsidiary's Clinical Trials for SARS-CoV-2 Booster Shot	17.07.23
Livzon Pharma Raises Cap in Extended Purchase Agreement to 39 Million Yuan	03.07.23
China Gives New Drug Application Approval to Mabpharm's Anti-Asthma Therapy	24.05.23
Mabpharm Grants Jemincare Pharma Unit Promotion Rights to Asthma Drug	13.04.23
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2022	24.03.23
Chinese Regulator Accepts Mabpharm's New Drug Application for Colorectal Cancer Treatment	15.03.23
Mabpharm Limited Announces New Drug Application of CMAB009	14.03.23
Livzon Pharma's COVID vaccine gets approval as booster in China	02.09.22
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2022	26.08.22
China Approves Clinical Trials for Mabpharm's Psoriasis Treatment	28.07.22
Mabpharm Limited Approves the Clinical Trial Application of CMAB015 for the Treatment of Psoriasis and Ankylosing Spondylitis	27.07.22
Chinese Regulator Approves Mabpharm's Clinical Trial for New Drug	06.07.22
Mabpharm Limited Announces Approval by National Medical Products Administration of China for the Clinical Trial Application of Biological Class I New Drug Cmab017	05.07.22
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2021	25.03.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Mabpharm Limited

Aktien

A2PK2Q

KYG5780F1046

2181

Andere Sprachen

Filter